CA Patent

CA2607098C — Dispersible bosentan tablet

Assigned to Actelion Pharmaceuticals Ltd · Expires 2012-04-10 · 14y expired

What this patent protects

The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2- hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]- benzenesulfonamide.

USPTO Abstract

The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2- hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]- benzenesulfonamide.

Drugs covered by this patent

Patent Metadata

Patent number
CA2607098C
Jurisdiction
CA
Classification
—
Expires
2012-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.